Clinical trials: Lipids Metabolism
Contraception
Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive
The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism.
- Trial name
- NCT00185224
- Testing
- EV/DNG (Qlaira, BAY86-5027, SH T00658K), SH D00264A (Triquilar)
- Where
- Germany
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bayer
Hypercholesterolemia, Coronary Heart Disease
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and…
- Trial name
- POLARIS (NCT00653588)
- Testing
- Rosuvastatin, Atorvastatin
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.
- Trial name
- NCT02824003
- Testing
- ISIS-GCGRRx
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypercholesterolemia
Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Primary Objective: Injection Site Tolerability Secondary Objective: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01448304
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current standard treatment with other statins for the treatment of dyslipidemia in moderate, moderately-high and high-risk participants.
- Trial name
- VYCTORY (NCT01587235)
- Testing
- Ezetimibe/simvastatin, Other Statin
- Sponsor
- Organon and Co
Hypertriglyceridemia
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG).
- Trial name
- MUIR-3 (NCT06347133)
- Testing
- Plozasiran Injection
- Where
- 235 sites in United States, Argentina and 13 more
- Volunteers
- 1,456 people
- Sponsor
- Arrowhead Pharmaceuticals
Healthy Participants
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative…
- Trial name
- NCT07316608
- Testing
- Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Dyslipidemia
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
The objectives of this study is To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment.
- Trial name
- NCT01893515
- Testing
- PRC-4016
- Where
- 39 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pronova BioPharma
Elevated LDL Cholesterol
Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of…
- Trial name
- NCT01362218
- Testing
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril), Simvastatin, ramipril, acetylsalicylic acid
- Where
- Spain
- Volunteers
- 107 people
- Sponsor
- Ferrer Internacional S.A.
Dyslipidemia
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.
- Trial name
- NCT00748852
- Testing
- JTT-302
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Shionogi Inc.
Hypercholesterolemia, Coronary Heart Disease
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- GRAVITY (NCT00525824)
- Testing
- Rosuvastatin (Crestor), Ezetimibe, Simvastatin
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 1,743 people
- Sponsor
- AstraZeneca
Hyperlipidemia
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
- Trial name
- PLANET II (NCT00296400)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 107 sites in United States, Brazil and 9 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Familial Hypercholesterolemia - Heterozygous
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP)…
- Trial name
- LIBerateKids (NCT07102511)
- Testing
- lerodalcibep 300 mg Monthly SC
- Where
- 7 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- LIB Therapeutics LLC
Hypertriglyceridemia
Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides
The hypothesis of this study is that DCCR is effective as both monotherapy and in combination with a statin in lowering triglycerides in subjects with very high triglycerides
- Trial name
- NCT00973271
- Testing
- 290 mg DCCR, 435 mg DCCR, 135 mg fenofibric acid
- Sponsor
- Essentialis, Inc.
Hyperlipidemia
Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
The Purpose of this study is to determine the safety and tolerability of 1-MNA, a drug that is intended to be used in the treatment of elevated levels of blood fats.
- Trial name
- PNAI-002 (NCT00685737)
- Testing
- 1-MNA
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pharmena North America
Chronic Smokers, Hyperlipidemia
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate…
- Trial name
- NCT02203227
- Testing
- BioTurmin (Curcuma longa rhizomes extract), BioTurmin-WD (Water dispersible curcuminoids), MaQxan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Olive Lifesciences Pvt Ltd
Dyslipidaemia
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam…
- Trial name
- NCT06671405
- Testing
- AZD0780, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metachromatic Leukodystrophy (MLD)
Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Objectives: The overall objective is to evaluate the safety, efficacy and pharmacokinetics (PK) of rhASA treatment in patients with late infantile MLD.
- Trial name
- NCT00418561
- Testing
- rhASA - Dose Level 1, rhASA - Dose Level 2, rhASA - Dose Level 3
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Shire
To Determine Bioequivalence Under Fed Conditions
A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study
The purpose of this study is to compare the bioavailability of Par Lisinopril 40 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R).
- Trial name
- NCT01380431
- Testing
- Lisinopril
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.